SAN DIEGO, July 20, 2026
Oncolytics Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) whose disease has progressed after or become intolerant to one or more prior lines of systemic therapy. The designation represents another important regulatory milestone for the company’s lead immunotherapy and strengthens its strategy to advance pelareorep toward potential registration in gastrointestinal cancers. Fast Track designation provides opportunities for closer collaboration with the FDA, including more frequent regulatory interactions, rolling review of a future Biologics License Application (BLA), and potential eligibility for Priority Review, accelerating development for an area where no FDA-approved therapies currently exist after failure of first-line standard treatment.
Fast Track Designation Supports Registrational Development Strategy
The FDA’s decision follows positive regulatory feedback received during an April 2026 meeting in which Oncolytics discussed a potential registrational development pathway for pelareorep in advanced SCAC. According to the company, the agency’s guidance established a clear regulatory framework for advancing the program into a pivotal clinical study. This latest designation is the third Fast Track designation awarded to pelareorep in gastrointestinal cancers, following previous designations in KRAS-mutated metastatic colorectal cancer and pancreatic cancer. Together, these regulatory achievements further validate pelareorep’s clinical development strategy while reducing regulatory uncertainty as the company pursues commercialization opportunities across multiple difficult-to-treat gastrointestinal malignancies.
Clinical Data Demonstrate Encouraging Outcomes in Advanced SCAC
The Fast Track designation is supported by encouraging findings from the ongoing GOBLET clinical study, which is evaluating pelareorep in combination with a checkpoint inhibitor in patients with advanced SCAC whose disease progressed following previous treatment. Previously reported clinical data demonstrated an objective response rate of approximately 30%, exceeding historical response rates observed in this treatment setting. Patients also achieved a median duration of response of approximately 15.5 months, compared with historical outcomes of about 9.5 months, while the 12-month overall survival rate reached 82%, substantially higher than previously reported survival rates. These findings suggest that pelareorep’s dual mechanism of action, which combines direct tumor cell targeting with activation of innate and adaptive anti-tumor immune responses, may significantly enhance the effectiveness of checkpoint inhibitor therapy in advanced anal cancer.
Advertisement
Pelareorep Expands Regulatory Momentum Across Gastrointestinal Cancers
Pelareorep is an investigational intravenously delivered immunotherapy designed to selectively replicate within tumor cells while stimulating both innate and adaptive immune responses, transforming immunologically “cold” tumors into more treatment-responsive “hot” tumors. Beyond anal cancer, the therapy continues to demonstrate clinical potential across several gastrointestinal malignancies, including colorectal and pancreatic cancer, where it has also received FDA Fast Track designation. With checkpoint inhibitor plus chemotherapy now established as the standard first-line treatment for advanced SCAC, patients who relapse have no FDA-approved therapeutic options, representing an estimated $1 billion annual U.S. market opportunity. The latest regulatory milestone further strengthens Oncolytics Biotech’s position as it advances pelareorep toward pivotal clinical studies and potential future regulatory submissions in multiple high-value oncology indications.
Source: Oncolytics Biotech press release
